GSK Diversification Pays Off With 21% Growth In Asia Pacific Sales: Emerging Markets Earnings Round Up (Part 1)
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline PLC April 27 released its first quarter results showing a handsome payoff for a diversification policy the pharmaceutical giant implemented three years ago. Although GSK overall sales declined 11%, strong growth in emerging markets and Japan helped offset losses from key products and bolster the net profit up by 14%.
You may also be interested in...
Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines
Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines
Merck Tagged With Non-compliance In Japan For 3,600 Physicians' Unjustified Honoraria
TOKYO - Merck & Co. Inc - known as MSD in Japan - is trying to remediate internal oversight measurers quickly after it received a "strict warning" from an independent compliance council for improper payments to a total of 3,604 physicians in Japan between January 2009 and December 2010, which constituted violations of the Fair Competition Code